ea0081p427 | Pituitary and Neuroendocrinology | ECE2022
Madhurya Kethireddi Keerthi
, Babu Parthasarathy Sathish
Background: Chronic SIAD with its disabling impact is challenging to manage in elderly patients as fluid restriction or demeclocycline often has a limited success. Tolvaptan is a novel selective antagonist of vasopressin receptor (V2R) which is safely used in patients with SIAD and other conditions with hypervolemia. We report a case of longest Tolvaptan use with significant challenges amongst our case series which we had previously publishedMethod: A Ca...